✦ LIBER ✦

Relapse and disability outcomes in patients with multiple sclerosis treated with fingolimod: subgroup analyses of the double-blind, randomised, placebo-controlled FREEDOMS study

✍ Scribed by Virginia Devonshire; Eva Havrdova; Ernst Wilhelm Radue; Paul O'Connor; Lixin Zhang-Auberson; Catherine Agoropoulou; Dieter Adrian Häring; Gordon Francis; Ludwig Kappos

Book ID: 114410023
Publisher: The Lancet
Year: 2012
Tongue: English
Weight: 212 KB
Volume: 11
Category: Article
ISSN: 1474-4465
DOI: 10.1016/s1474-4422(12)70056-x

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Safety and efficacy of fingolimod in pat

Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial

✍ Calabresi, Peter A; Radue, Ernst-Wilhelm; Goodin, Douglas; Jeffery, Douglas; Ram 📂 Article 📅 2014 🏛 The Lancet 🌐 English ⚖ 290 KB

Efficacy and safety of oral fumarate in

Efficacy and safety of oral fumarate in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study

✍ Ludwig Kappos; Ralf Gold; David H Miller; David G MacManus; Eva Havrdova; Volker 📂 Article 📅 2008 🏛 The Lancet 🌐 English ⚖ 209 KB

Effect of laquinimod on MRI-monitored di

Effect of laquinimod on MRI-monitored disease activity in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study

✍ G Comi; A Pulizzi; M Rovaris; O Abramsky; T Arbizu; A Boiko; R Gold; E Havrdova; 📂 Article 📅 2008 🏛 The Lancet 🌐 English ⚖ 143 KB

Effects of oral glatiramer acetate on cl

Effects of oral glatiramer acetate on clinical and MRI-monitored disease activity in patients with relapsing multiple sclerosis: a multicentre, double-blind, randomised, placebo-controlled study

✍ Massimo Filippi; Jerry S Wolinsky; Giancarlo Comi 📂 Article 📅 2006 🏛 The Lancet 🌐 English ⚖ 185 KB

Oral laquinimod in patients with relapsi

Oral laquinimod in patients with relapsing-remitting multiple sclerosis: 36-week double-blind active extension of the multi-centre, randomized, double-blind, parallel-group placebo-controlled study

✍ Comi, G.; Abramsky, O.; Arbizu, T.; Boyko, A.; Gold, R.; Havrdova, E.; Komoly, S 📂 Article 📅 2010 🏛 SAGE Publications 🌐 English ⚖ 307 KB

Repeated subcutaneous injections of IL12

Repeated subcutaneous injections of IL12/23 p40 neutralising antibody, ustekinumab, in patients with relapsing-remitting multiple sclerosis: a phase II, double-blind, placebo-controlled, randomised, dose-ranging study

✍ Benjamin M Segal; Cris S Constantinescu; Aparna Raychaudhuri; Lilianne Kim; Rosa 📂 Article 📅 2008 🏛 The Lancet 🌐 English ⚖ 180 KB